Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Biomatrix

This article was originally published in The Gray Sheet

Executive Summary

Biomatrix: Patient enrollment is under way for multi-center U.S. clinicals of Hylagel Uro following FDA approval of an investigational device exemption. Designed to treat urinary incontinence, the viscoelastic gel device is "injected intramuscularly to augment the soft connective tissue between the sphincter and the muscles of the urethra". Biomatrix anticipates its hylan B-based product will compete directly with Collagen's Contigen, a collagen-based urinary incontinence treatment approved in 1993 ("The Gray Sheet" Oct. 4, 1993, p. 1). Biomatrix expects to meet with FDA soon to discuss resubmission of its premarket approval application for its Hylaform viscoelastic gel for use in removing depressed scars and facial wrinkles, which was recently withdrawn. "The Gray Sheet" (Jan. 5, In Brief) incorrectly reported that the company would discuss with FDA the need for additional skin test data on allergic reactions and labeling changes. Biomatrix says there have been no reports of allergic reactions to Hylaform...

You may also be interested in...



Teva Leapfrogs Mylan And Sandoz On Linaclotide

A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.

Tecentriq Disappoints In Post-Surgery Bladder Cancer

Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.

Tiofarma Admits Involvement On UK Fludrocortisone

Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.

UsernamePublicRestriction

Register

MT009466

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel